The cluster of C-suite selling on a single date is worth monitoring, but the dollar amounts are too small to be a strong bearish signal. Watch for any upcoming clinical data readouts or financing announcements that could explain the timing.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 26 $14.80entry
- T+1 · 3mo ago −1.28%α −1.94% · $14.61
- T+5 · 3mo ago +1.05%α +1.17% · $14.96
- T+20 · 8w ago −31.62%α −31.77% · $10.12
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three top executives at Lyell Immunopharma (CEO, CSO, COO) sold a combined $187K in stock on the same day (Aug 21, 2026) at $15.54 per share. While the dollar amount is modest relative to the $361M market cap (~0.05%), the cluster of C-suite selling on a single date is notable. The sales are small and may be routine, but the timing and seniority warrant attention given the company's pre-revenue status and upcoming catalysts.
Key Financial Metrics
Key Facts
- CEO Seely Lynn sold 9,589 shares for $149K on Aug 21, 2026
- CSO Lee Gary K. sold 1,457 shares for $22.6K on Aug 21, 2026
- COO Hill Stephen J. sold 989 shares for $15.4K on Aug 21, 2026
- Total insider sales of $187K represent ~0.05% of $361M market cap
- All three sales were open-market transactions at $15.54/share
- No insider purchases in the cluster window
Financial Impact
Total insider sales of $187K, or ~0.05% of market cap, trivial in absolute terms but notable as a C-suite cluster
Risk Factors
- C-suite selling cluster could signal insider caution ahead of a catalyst
- Pre-revenue biotech with no approved products, high cash burn risk
- Small sample size of trades limits statistical significance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LYEL-1787728508248 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Viewing Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers